Samsung Biologics Co Ltd (207940) — Free Cash Flow Generation Index
Samsung Biologics Co Ltd (207940) has a Free Cash Flow Generation Index of 0.82x as of September 2025. Free cash flow of ₩505.48 Billion represents 1% of operating cash flow (₩619.30 Billion). Read Samsung Biologics Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Samsung Biologics Co Ltd Free Cash Flow Generation Index (2017–2024)
Historical FCF Generation Index trend for Samsung Biologics Co Ltd across 7 annual periods. Explore 207940 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Samsung Biologics Co Ltd (2017–2024)
Year-by-year Free Cash Flow Generation Index for Samsung Biologics Co Ltd. For the full company profile including market capitalisation, see Samsung Biologics Co Ltd market cap and net worth.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.17x | ₩281.73 Billion | ₩1.66 Trillion | ₩1.38 Trillion | ▼ -49.6% |
| 2023 | 0.34x | ₩560.90 Billion | ₩1.67 Trillion | ₩1.11 Trillion | ▲ +671.1% |
| 2022 | -0.06x | ₩-56.18 Billion | ₩953.05 Billion | ₩956.84 Billion | ▼ -180.1% |
| 2021 | 0.07x | ₩33.44 Billion | ₩454.60 Billion | ₩406.25 Billion | ▼ -72.2% |
| 2020 | 0.26x | ₩53.52 Billion | ₩202.09 Billion | ₩139.66 Billion | ▲ +101.6% |
| 2019 | -16.85x | ₩-171.04 Billion | ₩10.15 Billion | ₩192.84 Billion | ▼ -610.9% |
| 2017 | -2.37x | ₩-354.99 Billion | ₩149.82 Billion | ₩494.12 Billion | — |